Bezerra DT et al., 2022-11-14: Randomised pilot trial in 34 haemodialysis patients carrying Staphylococcus aureus in the nose: a single methylene blue photodynamic treatment (660 nm, 400 mW/cm2, 300 s, 0.01% methylene blue) left 71% culture-negative against 77% after a five-day mupirocin course, with no adverse events; of those negative after photodynamic therapy, 67% were recolonised within three months.
Photodynamic therapy is a feasible approach to treating nasal carriage of S aureus. Future larger studies should be conducted to determine whether photodynamic therapy is equivalent to the standard of care with mupirocin.
Abstract
Bezerra DT et al., 2022-11-14: Randomised pilot trial in 34 haemodialysis patients carrying Staphylococcus aureus in the nose: a single methylene blue photodynamic treatment (660 nm, 400 mW/cm2, 300 s, 0.01% methylene blue) left 71% culture-negative against 77% after a five-day mupirocin course, with no adverse events; of those negative after photodynamic therapy, 67% were recolonised within three months. Study type: randomised controlled pilot trial (NCT04047914). N=34 nasal S. aureus carriers on maintenance haemodialysis. Intervention: single PDT application, 660 nm, 400 mW/cm2, 300 s, methylene blue 0.01%; comparator topical mupirocin twice daily for 5 days. Outcomes: nasal swabs at 0, immediately post, 1 and 3 months, with proteomic identification and susceptibility testing. Funding: CNPq 3146682020-9. Country: Brazil. Limitation stated by the authors: only colonisation was assessed, not infectious complications. This is the strongest human randomised evidence in C9. Study type: randomized trial.
